Wedbush Lifts Earnings Estimates for Stoke Therapeutics

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Stock analysts at Wedbush upped their FY2024 earnings estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Tuesday, November 5th. Wedbush analyst L. Chico now forecasts that the company will earn ($2.00) per share for the year, up from their previous estimate of ($2.03). Wedbush has a “Outperform” rating and a $17.00 price target on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.10) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.62) EPS, FY2025 earnings at ($2.40) EPS, FY2026 earnings at ($2.51) EPS, FY2027 earnings at ($2.05) EPS and FY2028 earnings at ($0.76) EPS.

STOK has been the subject of several other research reports. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. HC Wainwright restated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. Needham & Company LLC restated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. Finally, Leerink Partners started coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price objective on the stock. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $20.83.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $13.27 on Friday. The firm has a 50 day simple moving average of $13.24 and a 200-day simple moving average of $13.70. Stoke Therapeutics has a 1-year low of $3.77 and a 1-year high of $17.58. The stock has a market cap of $698.64 million, a price-to-earnings ratio of -6.09 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The business had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million.

Insiders Place Their Bets

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the sale, the insider now directly owns 8,906,181 shares in the company, valued at $125,131,843.05. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 11.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Los Angeles Capital Management LLC raised its holdings in shares of Stoke Therapeutics by 54.3% in the 3rd quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company’s stock valued at $1,266,000 after purchasing an additional 36,240 shares in the last quarter. Mesirow Financial Investment Management Inc. purchased a new position in shares of Stoke Therapeutics in the 3rd quarter valued at $192,000. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of Stoke Therapeutics by 426.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after buying an additional 1,123,500 shares during the last quarter. Lynx1 Capital Management LP grew its position in shares of Stoke Therapeutics by 40.3% in the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after buying an additional 1,488,371 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after buying an additional 1,994 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.